The performance of companies tied to Sildenafil's past presents a intricate investment landscape. While the initial surge generated substantial profits , generic copies have significantly diminished revenue. Investing in connected pharmaceutical companies now requires a discerning assessment of proprietary rights , evolving patient shifts , and the